Odontoid Fracture Study Treated With Pulsed Electromagnetic Fields

NCT02281994 | Terminated FDA Device

• 1 other identifier: CP-1402ODFX
• Study Type: interventional
• Target: 24
• Locations: 0 countries
• Sites: N/A

Brief Summary

The hypothesis of this study is that PEMF treatment will improve odontoid fracture healing, compared with standard conservative care, in subjects 50 years of age and over diagnosed with Type II odontoid fractures, and this effect will be evident by 6 months post-injury. Subjects will be assessed for the presence of a Type II odontoid fracture by X-ray, MRI and CT scan. Subjects meeting eligibility criteria will be randomized in a 2:1 ratio (active: placebo control) to either the active or control device for 4 hours a day for 6 months. X-rays will be collected at 6 weeks, and at 3, 6 and 12 months to assess the fracture healing process, with flexion-extension x-rays collected at 3, 6 and 12 months. A CT scan will be performed at 6 months to confirm healing. Quality of Life measures (SF-36, VAS neck pain scale, NDI) will be collected at all visits (6 weeks, 3, 6 and 12 months). Study subjects will receive either an active Orthofix Cervical-Stim Model 2205OD or an inactive (placebo) Orthofix Cervical-Stim Model 2205OD device.

Conditions

Odontoid Fracture Type II

Keywords

PEMF; odontoid fracture; IDE; prospective

Outcome Measures

Primary Outcomes (1)

• Change over time of VAS pain

  Baseline, 6 week, 3 month, 6 month, 12 month

Study Arms (2)

Active PEMF

ACTIVE COMPARATOR

Active device emits Pulsed Electromagnetic Field (PEMF)

Device: Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD

Control/no PEMF

PLACEBO COMPARATOR

control/placebo device does not emit Pulsed Electromagnetic Field (PEMF)

Device: Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD

Interventions

Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD DEVICE

Active devices emit PEMF signal; control devices do not emit PEMF signal.

Active PEMF; Control/no PEMF

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must be 50 years of age or older at the time of consent
• Subject must have radiographic evidence (x-ray , MRI and CT scan) of a Type II odontoid fracture
• Subject must have MRI evidence that the fracture occurred within 30 days of study enrollment
• Subject must have VAS neck pain score of greater than 4 (\>4)
• Subject must have radiographic evidence that the fracture is displaced ≤ 5 mm in any direction and/or have a fracture gap of ≤ 3 mm due to angulation
• Subject must use a rigid cervical collar (Miami J, Philadelphia or Aspen) for a minimum of three months post-injury
• Subject must have a DEXA scan within 6 months prior to enrollment (can be done within one week of baseline visit)
• Subject must be willing and able to follow all study procedures and return for all study visits
• Subject must be willing to sign an Informed Consent Document

You may not qualify if:

• Subject has undergone systematic administration, within 30 days prior to the fracture, of any type of corticosteroid, antineoplastic, immunostimulation or immunosuppressive agents
• Subject is on chronic anticoagulation, or has a bleeding disorder
• Subject is pregnant, nursing or plans to become pregnant during the study
• Subject has a chronic Type II odontoid fracture that occurred more than 21 days prior to enrollment
• Subject has a Type II odontoid fracture displaced \>5 mm
• Subject has a mental or physical condition that would prevent him from complying with the study protocol, including the physician obtaining an accurate neurologic exam
• Subject was recommended for surgery to treat the fracture but subject refused surgery
• Subject is a prisoner
• Subject has participated in another clinical trial within the last 90 days

Sponsors & Collaborators

• Orthofix Inc.: lead

Study Officials

• Paul Arnold, MD

  The University of Kansas Hospital

  PRINCIPAL INVESTIGATOR

• Wellington Hsu, MD

  Northwestern University

  PRINCIPAL INVESTIGATOR

• Zachary Ray, MD

  Washington University School of Medicine

  PRINCIPAL INVESTIGATOR

• Khalid Abbed, MD

  Yale University

  PRINCIPAL INVESTIGATOR

• Joshua Ammerman, MD

  Washington Neurosurgical Associates

  PRINCIPAL INVESTIGATOR

• Jung Yoo, MD

  Oregon Health and Science University

  PRINCIPAL INVESTIGATOR

• Kelly Banagan, MD

  University of Maryland, College Park

  PRINCIPAL INVESTIGATOR

• Kee Kim, MD

  UC Davis

  PRINCIPAL INVESTIGATOR

• Sanjay Dhall, MD

  UC San Francisco

  PRINCIPAL INVESTIGATOR

• Amir Vokshoor, MD

  DISC Sports and Spine Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 26, 2014
• First Posted: November 4, 2014
• Study Start: September 1, 2014
• Primary Completion: September 1, 2019
• Study Completion: September 1, 2019
• Last Updated: October 26, 2021

Record last verified: 2021-10